Alert detail
FDA Approval: IBRANCE (PALBOCICLIB) — Type 1 - New Molecular Entity
Policy ID: FDA-NDA207103Specialty: Multi-specialtyAdded: 6/27/2026Effective: 2015-02-03federal register
Full alert analysis requires a subscription
Subscribe to access the complete alert summary, AI-generated action recommendations, source document links, LCD revision comparisons, and related alerts.